Urinary leukotriene E4 excretion is increased in type 1 diabetic patients

Morrish, 2001, Mortality and causes of death in the WHO multinational study of vascular disease in diabetes, Diabetologia, 44, S14, 10.1007/PL00002934 Tracy, 2002, Inflammation in cardiovascular disease: cart, horse or both—revisited, Arterioscler Thromb Vasc Biol, 22, 1514, 10.1161/01.ATV.0000035403.39442.DB Ridker, 2004, Established and emerging plasma biomarkers in the prediction of first atherothrombotic events, Circulation, 109, IV6, 10.1161/01.CIR.0000133444.17867.56 Natarajan, 2004, Lipid inflammatory mediators in diabetic vascular disease, Arterioscler Thromb Vasc Biol, 24, 1542, 10.1161/01.ATV.0000133606.69732.4c Davi, 1999, In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and Vitamin E supplementation, Circulation, 99, 224, 10.1161/01.CIR.99.2.224 Davi, 2003, Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus: role of interleukin-6 and disease duration, Circulation, 107, 3199, 10.1161/01.CIR.0000074205.17807.D0 Hishinuma, 1999, Urinary thromboxane A2/prostacyclin balance reflects the pathological state of a diabetic, Prostaglandins Other Lipid Mediat, 58, 263, 10.1016/S0090-6980(99)00029-5 Antonipillai, 1996, A 12-lipoxygenase product, 12-hydroxyeicosatetraenoic acid, is increased in diabetics with incipient and early renal disease, J Clin Endocrinol Metab, 81, 1940, 10.1210/jc.81.5.1940 Kumlin, 2000, Measurement of leukotrienes in humans, Am J Respir Crit Care Med, 161, S102, 10.1164/ajrccm.161.supplement_1.ltta-20 Taylor, 1989, Urinary leukotriene E4 after antigen challenge and in acute asthma and allergic rhinitis, Lancet, 1, 584, 10.1016/S0140-6736(89)91611-5 Folco, 2000, Leukotrienes in cardiovascular diseases, Am J Respir Crit Care Med, 161, S112, 10.1164/ajrccm.161.supplement_1.ltta-22 Porreca, 1996, Cysteinyl leukotriene D4 induced vascular smooth muscle cell proliferation: a possible role in myointimal hyperplasia, Thromb Haemost, 76, 99, 10.1055/s-0038-1650530 Spanbroek, 2003, Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis, Proc Natl Acad Sci USA, 100, 1238, 10.1073/pnas.242716099 Dwyer, 2004, Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis, N Engl J Med, 350, 29, 10.1056/NEJMoa025079 Helgadottir, 2004, The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke, Nat Genet, 36, 233, 10.1038/ng1311 Helgadottir, 2005, Association between the gene encoding 5-lipoxygenase-activating protein and stroke replicated in a scottish population, Am J Hum Genet, 76, 505, 10.1086/428066 Allen, 1993, Enhanced excretion of urinary leukotriene E4 in coronary artery disease and after coronary artery bypass surgery, Coron Artery Dis, 4, 899, 10.1097/00019501-199310000-00009 Carry, 1992, Increased urinary leukotriene excretion in patients with cardiac ischemia. In vivo evidence for 5-lipoxygenase activation, Circulation, 85, 230, 10.1161/01.CIR.85.1.230 Hakonarson, 2005, Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial, JAMA, 293, 2245, 10.1001/jama.293.18.2245 Roth, 1983, Vascular responsiveness and eicosanoid production in diabetic rats, Diabetologia, 24, 372, 10.1007/BF00251827 Hardy, 2001, Cysteinyl leukotrienes modulate angiotensin II constrictor effects on aortas from streptozotocin-induced diabetic rats, Arterioscler Thromb Vasc Biol, 21, 1751, 10.1161/hq1201.098769 Hardy, 2005, 5-Lipoxygenase expression and activity in aorta from streptozotocin-induced diabetic rats, Prostaglandins Other Lipid Mediat, 75, 91, 10.1016/j.prostaglandins.2004.10.002 Valdivielso, 2003, Inhibition of 5-lipoxygenase activating protein decreases proteinuria in diabetic rats, J Nephrol, 16, 85 Parlapiano, 1999, The relationship between glycated hemoglobin and polymorphonuclear leukocyte leukotriene B4 release in people with diabetes mellitus, Diabetes Res Clin Pract, 46, 43, 10.1016/S0168-8227(99)00065-0 Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diab Care (2002);25:S5–20. Qiu, 1996, Simplified method for measuring urinary leukotriene E4, J Chromatogr B Biomed Appl, 677, 152, 10.1016/0378-4347(95)00468-8 Wu, 1996, Determination of LTE4 in human urine by liquid chromatography coupled with ionspray tandem mass spectrometry, J Mass Spectrom, 31, 987, 10.1002/(SICI)1096-9888(199609)31:9<987::AID-JMS382>3.0.CO;2-F Kumlin, 1995, Validation and application of a new simple strategy for measurements of urinary leukotriene E4 in humans, Clin Exp Allergy, 25, 467, 10.1111/j.1365-2222.1995.tb01079.x Shanmugam, 2004, Molecular mechanisms of high glucose-induced cyclooxygenase-2 expression in monocytes, Diabetes, 53, 795, 10.2337/diabetes.53.3.795 Basu, 2005, Type 1 diabetes is associated with increased cyclooxygenase- and cytokine-mediated inflammation, Diab Care, 28, 1371, 10.2337/diacare.28.6.1371 Suzuki, 2003, Determination of urinary 12(S)-hydroxyeicosatetraenoic acid by liquid chromatography–tandem mass spectrometry with column-switching technique: sex difference in healthy volunteers and patients with diabetes mellitus, J Chromatogr B Anal Technol Biomed Life Sci, 783, 383, 10.1016/S1570-0232(02)00666-9 Natarajan, 1993, Elevated glucose and angiotensin II increase 12-lipoxygenase activity and expression in porcine aortic smooth muscle cells, Proc Natl Acad Sci USA, 90, 4947, 10.1073/pnas.90.11.4947 Stanke-Labesque, 2001, Cysteinyl leukotrienes are involved in angiotensin II-induced contraction of aorta from spontaneously hypertensive rats, Cardiovasc Res, 49, 152, 10.1016/S0008-6363(00)00238-8 Stanke-Labesque, 2002, Involvement of cysteinyl leukotrienes in angiotensin II-induced contraction in isolated aortas from transgenic (mRen-2)27 rats, J Hypertens, 20, 263, 10.1097/00004872-200202000-00016 Stanke-Labesque, 2000, Angiotensin II-induced contractions in human internal mammary artery: effects of cyclooxygenase and lipoxygenase inhibition, Cardiovasc Res, 47, 376, 10.1016/S0008-6363(00)00112-7 Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000;355:253. Funk, 2005, Leukotriene modifiers as potential therapeutics for cardiovascular disease, Nat Rev Drug Discov, 22, 22